Carlsmed, Inc. Revenue from Contract with Customer, Including Assessed Tax
Carlsmed, Inc. (CARL) reported Revenue from Contract with Customer, Including Assessed Tax of $18.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax · last filed 2026-08-05
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-06-30 was $18.94M, a 56.75% increase year-over-year.
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2026-03-31 was $16.12M, a 58.17% increase year-over-year.
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-12-31 was $15.16M, a 61.19% increase year-over-year.
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for the quarter ending 2025-09-30 was $13.07M, a 98.39% increase year-over-year.
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for fiscal 2025 was $50.51M, a 85.94% increase from fiscal 2024.
- Carlsmed, Inc. revenue from contract with customer, including assessed tax for fiscal 2024 was $27.16M.
| Period end | Revenue from Contract with Customer, Including Assessed Tax 3 month | Revenue from Contract with Customer, Including Assessed Tax 6 month | Revenue from Contract with Customer, Including Assessed Tax 9 month | Revenue from Contract with Customer, Including Assessed Tax 12 month |
|---|---|---|---|---|
| 2026-06-30 | $18.94M 10-Q · filed 2026-08-05 | $35.06M 10-Q · filed 2026-08-05 | $50.22M derived: sum of 3 quarters · filed 2026-08-05 | $63.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $16.12M 10-Q · filed 2026-05-05 | $31.28M derived: sum of 2 quarters · filed 2026-05-05 | $44.35M derived: sum of 3 quarters · filed 2026-05-05 | $56.44M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $15.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $28.24M derived: sum of 2 quarters · filed 2026-02-25 | $40.32M derived: sum of 3 quarters · filed 2026-08-05 | $50.51M 10-K · filed 2026-02-25 |
| 2025-09-30 | $13.07M 10-Q · filed 2025-11-06 | $25.16M derived: sum of 2 quarters · filed 2026-08-05 | $35.35M 10-Q · filed 2025-11-06 | $44.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $12.08M 10-Q · filed 2026-08-05 | $22.27M 10-Q · filed 2026-08-05 | $31.68M derived: sum of 3 quarters · filed 2026-08-05 | $38.27M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $10.19M 10-Q · filed 2026-05-05 | $19.60M derived: sum of 2 quarters · filed 2026-05-05 | $26.19M derived: sum of 3 quarters · filed 2026-05-05 | $32.27M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $9.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $16.00M derived: sum of 2 quarters · filed 2026-02-25 | $22.08M derived: sum of 3 quarters · filed 2026-02-25 | $27.16M 10-K · filed 2026-02-25 |
| 2024-09-30 | $6.59M 10-Q · filed 2025-11-06 | $12.67M derived: sum of 2 quarters · filed 2025-11-06 | $17.76M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $6.08M 10-Q · filed 2025-08-28 | $11.17M 10-Q · filed 2025-08-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Orthofix Medical Inc. (OFIX) | $0.373B | ||
| ClearPoint Neuro, Inc. (CLPT) | United States | $0.446B | -15.74 |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Sight Sciences, Inc. (SGHT) | United States | $0.478B | -9.95 |
| NeuroPace Inc (NPCE) | United States | $0.480B | -28.52 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TACTILE SYSTEMS TECHNOLOGY INC (TCMD) | United States | $0.519B | 27.16 |